Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial

Gili Kenet, Hervé Chambost, Christoph Male, Thierry Lambert, Susan Halimeh, Tatiana Chernova, Maria Elisa Mancuso, Julie Curtin, Christine Voigt, Yanyan Li, Iris Jacobs, Elena Santagostino, PROLONG-9FP Investigator Study Group, Gili Kenet, Hervé Chambost, Christoph Male, Thierry Lambert, Susan Halimeh, Tatiana Chernova, Maria Elisa Mancuso, Julie Curtin, Christine Voigt, Yanyan Li, Iris Jacobs, Elena Santagostino, PROLONG-9FP Investigator Study Group

Abstract

A global phase 3 study evaluated the pharmacokinetics, efficacy and safety of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 27 previously treated male children (1-11 years) with severe and moderately severe haemophilia B (factor IX [FIX] activity ≤2 IU/dl). All patients received routine prophylaxis once every seven days for up to 77 weeks, and treated any bleeding episodes on-demand. The mean terminal half-life of rIX-FP was 91.4 hours (h), 4.3-fold longer than previous FIX treatment and clearance was 1.11 ml/h/kg, 6.4-fold slower than previous FIX treatment. The median (Q1, Q3) annualised spontaneous bleeding rate was 0.00 (0.00, 0.91) and was similar between the <6 years and ≥6 years age groups, with a weekly median prophylactic dose of 46 IU/kg. In addition, patients maintained a median trough level of 13.4 IU/dl FIX activity on weekly prophylaxis. Overall, 97.2 % of bleeding episodes were successfully treated with one or two injections of rIX-FP (95 % CI: 92 % to 99 %), 88.7 % with one injection, and 96 % of the treatments were rated effective (excellent or good) by the Investigator. No patient developed FIX inhibitors and no safety concerns were identified. These results indicate that rIX-FP is safe and effective for preventing and treating bleeding episodes in children with haemophilia B with weekly prophylaxis. Routine prophylaxis with rIX-FP at treatment intervals of up to 14 days are currently being investigated in children with severe and moderately severe haemophilia B. Clinicaltrials.gov (NCT01662531).

Keywords: Haemophilia B; factor IX; on-demand treatment; prophylactic regimen; rIX-FP.

Conflict of interest statement

G.K., H.C., C.M., T.L., S.H., T.C., M.E.M, J.C. and E.S. received research support from CSL Behring to conduct the study. G.K. received honoraria for speaking and/or for consulting from Opko Biologics, Alnylam, Bayer, Pfizer, Novo Nordisk and research grants from BPL, Baxalta, Pfizer, Opko Biologics. H.C. received honoraria for speaking and/or for consulting from CSL Behring, Bayer Healthcare, Baxter Biosciences, LFB, Novo Nordisk and Pfizer. C.M. has received honoraria for speaking and travel support from Baxter, Bayer, Biotest, CSL Behring, Novo Nordisk and Pfizer. T.L. has received honoraria for speaking and/or for consulting from Baxalta, Bayer, Biogen Ipsen, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer and Roche. S.H. received research grant and speakers honorarium from Bayer Healthcare GmbH, Baxalta Innovations GmbH, Biotest AG, CSL Behring GmbH, LFB GmbH, Novartis Pharma GmbH, Novo Nordisk Pharma GmbH, Octapharma GmbH and Pfizer Pharma GmbH. M.E.M. received speaker and consulting fees from CSL Behring, Bayer Healthcare, Pfizer, Baxalta, Novo Nordisk and Sobi/Biogen Idec. J.C. received honoraria for speaking and/or for consulting from CSL Behring, Baxter Biosciences, Biogen Idec and Novo Nordisk. E.S. received honoraria for speaking and/or for consulting from CSL Behring, Bayer, Baxter/Baxalta, Pfizer, NovoNordisk, Roche, Sobi/Biogen Idec, Biotest, Kedrion, Octapharma and Grifols and received unrestricted research grants from NovoNordisk and Pfizer. C.V., Y.L. and I.J. were employed at CSL Behring.

Figures

Figure 1:
Figure 1:
Patient enrolment and study flow diagram. The diagram shows the flow and disposition of patients in the study. Following screening, 27 patients were enrolled in the study. All patients participated in PK evaluation of 50 IU/kg rIX-FP. A subset of patients (n=17) also participated in a PK evaluation of their previous FIX product (pdFIX or rFIX). All patients were assigned weekly prophylaxis with a dose of 35–50 IU/kg. All patients completed the study. FIX, factor IX; pdFIX, plasma-derived FIX; PK, pharmacokinetics; rFIX, recombinant FIX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.
Figure 2:
Figure 2:
FIX activity after injection of a single dose of rIX-FP or previous FIX product (PK population). Mean baseline-uncorrected FIX activity after administration of a single infusion of 50 IU/kg of rIX-FP or 50 IU/kg previous FIX product (pdFIX or rFIX). FIX activity was measured in IU/dl. Vertical bars represent standard deviation. FIX, factor IX; pdFIX, plasma-derived FIX; PK, pharmacokinetic; rFIX, recombinant FIX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.

References

    1. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801–1809.
    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2012; 19: e1-e47.
    1. RIXUBIS Package Insert. Available at: . Accessed 22nd February 2016.
    1. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16: 20–24.
    1. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–2411.
    1. Martinowitz U, Lissitchkov T, Lubetsky A, et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 2015; 21: 784–790.
    1. International Conference on Harmonization. Harmonized Tripartite Guideline: Guideline for Good Clinical Practice (E6). ICH. 1996. Available at: . Accessed February 22, 2016.
    1. European Medicines Agency. Committee for medicinal products for human use (CHMP), Guideline in the Clinical Investigation of Recombinant and Human Plasma-Derived Factor IX Products. EMEA. 2009. CHMP/BPWP/144552/2009.
    1. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247–251.
    1. Windyga J, Lissitchkov T, Stasyshyn O, et al. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study. Haemophilia 2014; 20: 651–658.
    1. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384–386.
    1. Lee M, Morfini M, Schulman S, et al. Scientific and Standardization Committee Communication: The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Available at: . Accessed February 22, 2016.
    1. Rallapalli PM, Kemball-Cook G, Tuddenham EG, et al. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013; 11: 1329–1340.
    1. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127: 1761–1769.
    1. Alprolix Package Insert. Available at: . Accessed 22nd February 2016.
    1. Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880–3886.
    1. Roth DA. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600–3606.
    1. Benefix Package Insert. Available at: . Accessed February 22, 2016.
    1. Journeycake JM. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727–1731.
    1. Price VE, Carcao M, Connolly B, et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 737–742.
    1. Ranta S, Kalajoki-Helmiö T, Pouttu J, et al. MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia. Haemophilia 2011; 18: 521–526.
    1. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935–1939.
    1. HGVS. Nomenclature for the description of sequence variations homepage. Available at. Accessed December 10, 2015.
    1. Goodeve AC, Reitsma PH, McVey JH. Nomenclature of genetic variants in hemostasis. J Thromb Haemost 2011; 9: 852–855.
    1. CDC Hemophilia B Mutation Project (CHBMP) F9 Database. Available at: . Accessed February 22, 2016.
    1. Broderick CR, Herbert RD, Latimer J. Association between physical activity and risk of bleeding in children with hemophilia. J Am Med Assoc 2012; 308: 1452–1459.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel